DDInter535 DDInter1077
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is bound by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diclofenamide
Diclofenamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide {u} (Compound) upregulates {v} (Gene) RBM6
RBM6 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Diazoxide {u} (Compound) upregulates {v} (Gene) P4HTM
P4HTM {u} (Gene) is downregulated by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is bound by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Diazoxide (Compound) upregulates RBM6 (Gene) and RBM6 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Diazoxide (Compound) upregulates P4HTM (Gene) and P4HTM (Gene) is downregulated by Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide